Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496174 | 0.92 | BRAF (0.48) | BRAFEGFRERBB2LRRK2 | |
| SCHEMBL9933164 | 0.89 | BRAF (0.51) | BRAFLRRK2 | |
| SCHEMBL1496220 | 0.87 | BRAF (0.50) | BRAFEGFRERBB2LRRK2 | |
| SCHEMBL1496222 | 0.87 | BRAF (0.62) | BRAF | |
| SCHEMBL9933287 | 0.87 | BRAF (0.55) | BRAF | |
| SCHEMBL1496248 | 0.87 | BRAF (0.51) | BRAFEGFRERBB2LRRK2 | |
| SCHEMBL1495246 | 0.87 | BRAF (0.48) | BRAFEGFRERBB2LRRK2 | |
| SCHEMBL1496268 | 0.87 | BRAF (0.48) | BRAFEGFRERBB2LRRK2 | |
| SCHEMBL9932957 | 0.86 | BRAF (0.53) | BRAF | |
| SCHEMBL1496229 | 0.86 | BRAF (0.46) | BRAFEGFRERBB2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470532-A1 | 1H-PYRAZOLO [ 3, 4-B]PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157452-A1 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157452-A1 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025968-A1 | 1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011025968-A1 | 1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157452-A1 | 1H-PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE | BRAF, RAF1, ARAF | BRAF 1/4885MEN1 1472/4885KMT2A 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.